deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04157751

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)

Sponsor: Boehringer Ingelheim

Conditions Heart Failure
Interventions Empagliflozin Placebo to Empagliflozin
Updated 25 times since 2019 Last updated: Jun 28, 2022 Started: May 18, 2020 Primary completion: May 28, 2021 Completion: Jun 2, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heart Failure and is currently completed. Boehringer Ingelheim leads this study, which shows 25 recorded versions since 2020 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE3

▶ Show 20 earlier versions

  1. Sep 2021 — Jul 2022 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  2. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  3. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  4. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  5. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  6. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  9. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  10. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  11. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  12. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  13. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  14. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  15. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE3

  16. Apr 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE3

  17. Mar 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE3

  18. Feb 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE3

  19. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE3

  20. Dec 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
  • Eli Lilly and Company
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalborg, Denmark , Aalst, Belgium , Amarillo, United States , Apeldoorn, Netherlands , Atlanta, United States , Beijing, China , Berlin, Germany , Boston, United States , Bremen, Germany and 100 more locations